

# Become part of the community helping to address immunotherapy cancer care



Do you want to make a difference in the lives of people who are living with immunotherapy cancer care? Now you can by joining BESPOKE IO—a new registry study currently enrolling patients. This study will determine the effects of clinical outcomes using Signatera,™ a simple blood test that can help determine whether you are responding to immunotherapy. The information from this study may be used to help doctors address immunotherapy cancer care with future patients.

### You may qualify if all of the following criteria apply:

- You are a colorectal cancer, non-small cell lung cancer or melanoma patient
- Your doctor selected you to receive the Signatera test as part of your routine care
- You are clinically eligible and planned to receive an antineoplastic agent that works by immune checkpoint blockade, anti-PD-1, anti-CTLA-4 or anti-PD-L1
- You are able to tolerate blood draws from the arm
- You are 18 years of age or older

Learn more at [natera.com/BESPOKE-IO](https://natera.com/BESPOKE-IO)

Talk to your doctor today about enrolling in BESPOKE IO



**Signatera™**  
Residual disease test (MRD)



**Study name:**  
**BESPOKE Study of ctDNA Guided immunotherapy**

**Study ID:**  
**NCT04761783**

**Currently activating sites and enrolling patients**

